Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
POU domain class 5 transcription factor 1, widely known as OCT4, is a master regulator of pluripotency and self-renewal in embryonic stem cells and germ cells [1, 3, 5]. It functions by binding to specific octamer DNA motifs and forming synergistic complexes with other factors like SOX2 and NANOG to maintain an undifferentiated cellular state [5, 9, 10]. While typically silenced in adult somatic tissues, its aberrant re-expression is a hallmark of cancer stem cells (CSCs) in various malignancies, including germ cell tumors, lung, bladder, and breast cancers [2, 11, 21]. In the tumor microenvironment, OCT4 activity drives proliferation, metastasis, and acquired resistance to chemotherapeutic agents like cisplatin [12, 13, 21]. Therapeutic strategies, such as using all-trans retinoic acid to repress OCT4 transcription, aim to sensitize tumors to treatment by eradicating the resilient stem cell-like population [12].
Transcriptional repression of stemness genes and inhibition of cancer stem cell maintenance [7, 12].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on POU domain class 5 transcription factor 1 (OCT4).